US FDA clears Oxford Biomedica's cancer vaccine TroVax for further development
07 July 2009
Katie McQue
The US
FDA has given the go-ahead for
Oxford Biomedica to resume developing its novel cancer vaccine TroVax in renal cancer, and pursue further indications in multiple metastatic cancer settings, including colorectal, ovarian and triple-negative breast cancers.
The decision was made after the...
Please Login to read the full article.
07 July 2009
Katie McQue
The decision was made after the...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Argos to begin Phase III of renal carcinoma drug in combination with sunitinib
- 4SC steps up partnering efforts as key resminostat data comes in ahead of schedule
- AVEO/Astellas 2012 filing for tivozanib as it beats Nexavar in Ph III kidney cancer trial
- ODAC backs Pfizer kidney cancer drug as second-line treatment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
